Suspension platform development for lentiviral vector manufacturing

Scroll Down

Development of a Transfection-based, Scalable, Serum-Free, Single-Use Suspension Platform for Manufacturing Lentiviral Vector Manufacturing

Lentiviral vectors (LVV) are commonly used to deliver genetic information into cells for gene expression for gene and cell therapies. However, clinical and commercial supply of cGMP lentiviral vectors is under considerable global pressure due to limited scalability of adherent HEK293T cell line production systems.

Genezen has developed a new transfection-based, serum-free suspension platform to support lentiviral vector manufacturing in our upcoming GMP facility using a HEK293T-based suspension cell line: GL293T.

This new fully scalable GMP suspension platform enables efficient manufacturing process with the benefit of a yield up to 4E7 TU/mL.

Download our poster presentation from ASGCT 2021 by completing the form to the right for further insight into how the new GL293T was developed and how it could be used in your next lentivirus project.

You may also be interested in...

Genezen completes cGMP-lentiviral and retroviral vector…

Genezen, a cell and gene therapy Contract Development and Manufacturing Organization...

Read more

Genezen announces launch of Scientific Advisory…

Leading experts in cell and gene therapy will provide guidance to...

Read more

Overcoming development and manufacturing challenges with…

As efficient and effective tools for gene transduction and delivering genes...

Read more

Retroviruses in CAR-T therapies: From gamma…

Introduction In recent years, chimeric antigen receptor T (CAR-T) cells have...

Read more